Tango Therapeutics (TNGX) Other Accumulated Expenses (2020 - 2026)

Tango Therapeutics' Other Accumulated Expenses history runs 7 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 21.23% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.6 million (down 21.23% YoY), while the FY2025 annual figure was $1.3 million, down 25.71% from the prior year.
• Other Accumulated Expenses was $1.6 million for Q1 2026 at Tango Therapeutics, up from $1.3 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $2.7 million in Q3 2024 to a low of $900000.0 in Q1 2022.
• Historically, Other Accumulated Expenses has averaged $1.6 million across 5 years, with a median of $1.6 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses soared 90.83% in 2024, then sank 37.04% in 2025.
• A 5-year view of Other Accumulated Expenses shows it stood at $1.3 million in 2022, then advanced by 1.58% to $1.3 million in 2023, then soared by 34.81% to $1.7 million in 2024, then dropped by 25.71% to $1.3 million in 2025, then grew by 20.87% to $1.6 million in 2026.
• The last three Other Accumulated Expenses figures came in at $1.6 million (Q1 2026), $1.3 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.